About XenTech

Emilie received her Ph.D. degree in Cellular Biology and Physiopathology in 2016 from Bordeaux University (INSERM U1035, Bordeaux). She has a 7 years’ academic experience in the field of pediatric cancer.

During her Ph.D., she conducted in vitro and ex vivo studies on hepatoblastoma cell lines and PDX models for which she established molecular characterizations. She then moved to Curie Institute (UMR 3347/U1021, Curie Institute, Orsay) where she worked on medulloblastoma PDX models and participated to the establishment and the multi-omics characterization of a large cohort of medulloblastoma patient tumors.

Since she joined Xentech in 2021, she is in charge of the project management of in vitro and in vivo studies for R&D projects as well as Contract Research Services. She also is responsible for managing molecular data and for the PDX models molecular characterization.

Delphine received her Ph.D. degree in Biological Sciences from Orléans University (France) in 2004. She has an academic experience in molecular immunology and embryology, and she worked as study manager at the CNRS UMR6218 lab in Orléans. Delphine joined XenTech in 2008. . Delphine is responsible for managing in vivo efficacy studies in our preclinical research services department.

Marie was promoted to Study Director in April 2012. Prior to that she worked for 4 years in the field of preclinical oncology including 3 years at XenTech where she acquired an extensive knowledge of in vivo PDX studies and project management. Marie received a Master degree in bio-industrial technologies from Orléans University (France) in 2007.

She leads the Study Director team since 2022.

CEO XenTech

CEO Janvier Group Biosciences

CEO XenTech

CEO Janvier Group Biosciences

Vincent earned his PhD from the anti-cancer institute of Bordeaux and worked on the identification and characterization of genes modulating the sensitivity to anti-cancer agents targeting the DNA integrity.

Following a post-doc at the Erasmus Medical Center of Rotterdam where he worked on the deciphering of the Nucleotide Excision Repair machinery, Vincent developed and managed studies for more than 10 years in different preclinical CROs, mainly in the field of oncology and immune-oncology.

As Business Developer, Vincent explores and assists, alongside the whole team, every opportunity allowing to support preclinical programs in oncology with the PDX/PDX DC models and related services of Xentech.

Emilie received her Ph.D. degree in Cellular Biology and Physiopathology in 2016 from Bordeaux University (INSERM U1035, Bordeaux). She has a 7 years’ academic experience in the field of pediatric cancer.

During her Ph.D., she conducted in vitro and ex vivo studies on hepatoblastoma cell lines and PDX models for which she established molecular characterizations. She then moved to Curie Institute (UMR 3347/U1021, Curie Institute, Orsay) where she worked on medulloblastoma PDX models and participated to the establishment and the multi-omics characterization of a large cohort of medulloblastoma patient tumors.

Since she joined Xentech in 2021, she is in charge of the project management of in vitro and in vivo studies for R&D projects as well as Contract Research Services. She also is responsible for managing molecular data and for the PDX models molecular characterization.

PhD in immunology, François spent most of his career in the industry, first at Immunotech and then at Innate Pharma as a co-founder and Scientific Director for nearly 14 years, where he led the development of several antibodies now in clinical trials.

Co-founded of MImAbs with Thierry Jean in 2020, he’s been Scientific Director ever since. He alos took the CSO role at XenTech in Apr. 2023.

François is the author of more than 50 peer review publications, and 15 patent families.

Experimented CFO, with wide experience in several SME companies, both in B2C and B2B activities. Marie is in charge of financial well-being of the organization, financial projections, accounting services as well as Human Resources management. She masters financial strategies by forecasting capital, facilities, and staff requirements; identifies monetary resources and develops action plans. 

Delphine received her Ph.D. degree in Biological Sciences from Orléans University (France) in 2004. She has an academic experience in molecular immunology and embryology, and she worked as study manager at the CNRS UMR6218 lab in Orléans. Delphine joined XenTech in 2008. . Delphine is responsible for managing in vivo efficacy studies in our preclinical research services department.

Marie was promoted to Study Director in April 2012. Prior to that she worked for 4 years in the field of preclinical oncology including 3 years at XenTech where she acquired an extensive knowledge of in vivo PDX studies and project management. Marie received a Master degree in bio-industrial technologies from Orléans University (France) in 2007.

She leads the Study Director team since 2022.

Olivier has over 20 years of research experience in the field of immunology and oncology. He received his Ph.D in 1999 from University Paris Sud XI. Before he joined XenTech, he developed an original system of gene therapy targeted by antibody at Bioprotein Technologies and at Targatherapies, where he was in charge of the R&D. Then, Olivier was Head of the Oncology department (vitro and vivo) at Theraptosis (Pasteur Institute, Paris). Olivier is currently manager of XenTech’s cell biology department.

Laurent is an experienced Laboratory Animal Technician. Before working at XenTech, he worked at the CERB and Pierre Fabre Laboratories. He has over 20 years of experience in the field of toxicology and pharmacology studies in a GLP environment. At XenTech, Laurent is in charge of the implementation of the quality management system. He coordinates the improvement actions and manages the documentary system.